RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq:TLCR - News) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex®-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).
